What does Dr. Katrien Wierckx, endocrinologie do?

Dr. Katrien Wierckx, endocrinologie is a specialist medical practice in Oosterzele. Private Limited, started on 17 July 2019, 1 establishment.

What is the address of Dr. Katrien Wierckx, endocrinologie?

The registered office of Dr. Katrien Wierckx, endocrinologie is located at Rattepas 11A, 9860 Oosterzele.

Is Dr. Katrien Wierckx, endocrinologie still active?

Yes. According to the CBE (30 September 2026) Dr. Katrien Wierckx, endocrinologie is active, legal situation “Normale toestand”, started on 17 July 2019.

Is Dr. Katrien Wierckx, endocrinologie registered on Peppol?

Yes, Dr. Katrien Wierckx, endocrinologie is registered on the Peppol network with ID 0208:0730804532.

What is the enterprise number of Dr. Katrien Wierckx, endocrinologie?

The enterprise number of Dr. Katrien Wierckx, endocrinologie is BE0730804532.

When was Dr. Katrien Wierckx, endocrinologie founded?

Dr. Katrien Wierckx, endocrinologie was founded on 17 July 2019.

Who are the directors of Dr. Katrien Wierckx, endocrinologie?

According to the 2025 annual accounts, the directors of Dr. Katrien Wierckx, endocrinologie are: Katrien Wierckx.

Is Dr. Katrien Wierckx, endocrinologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 July 2019; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Katrien Wierckx, endocrinologie make in 2025?

Dr. Katrien Wierckx, endocrinologie posted a profit after taxes of € 277,930 in financial year 2025.

What is the revenue of Dr. Katrien Wierckx, endocrinologie?

As a small company, Dr. Katrien Wierckx, endocrinologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 388,057.

Dr. Katrien Wierckx, endocrinologie (Private Limited)

Dossier Dr. Katrien Wierckx, endocrinologie, printed on 30 September 2026 from databakkes.be/en/0730804532/dr-katrien-wierckx-endocrinologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Katrien Wierckx, endocrinologie from Oosterzele, company number BE0730804532, closed financial year 2025 with a result of € 277,930 after tax. For that financial year Dr. Katrien Wierckx, endocrinologie recorded a gross margin of € 388,057 and equity of € 201,191. Compared with financial year 2024, the result moved from € 216,198 to € 277,930. Profitable, and profit is growing. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.

What it is worth Healthy

€ 201,191

▼ 19% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 277,930

▲ 29% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 358,395

▲ 24% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 325,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 2,759

▼ 38% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 176,629

▼ 9% vs 2024

€ 18,061 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 18,679

▲ € 17,325 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 66,726

▲ 56% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 207,669 Gross margin 2022: € 207,669 First fiscal year in the series	€ 380,115 Gross margin 2023: € 380,115 ▲ 83% vs 2022 (€ 207,669) Favourable step	€ 303,444 Gross margin 2024: € 303,444 ▼ 20% vs 2023 (€ 380,115) Unfavourable step	€ 388,057 Gross margin 2025: € 388,057 ▲ 28% vs 2024 (€ 303,444) Favourable step	▲ 28%
Profit after taxes	€ 151,278 Profit after taxes 2022: € 151,278 First fiscal year in the series	€ 278,098 Profit after taxes 2023: € 278,098 ▲ 84% vs 2022 (€ 151,278) Favourable step	€ 216,198 Profit after taxes 2024: € 216,198 ▼ 22% vs 2023 (€ 278,098) Unfavourable step	€ 277,930 Profit after taxes 2025: € 277,930 ▲ 29% vs 2024 (€ 216,198) Favourable step	▲ 29%
Equity	€ 128,964 Equity 2022: € 128,964 First fiscal year in the series	€ 272,063 Equity 2023: € 272,063 ▲ 111% vs 2022 (€ 128,964) Favourable step	€ 248,261 Equity 2024: € 248,261 ▼ 9% vs 2023 (€ 272,063) Unfavourable step	€ 201,191 Equity 2025: € 201,191 ▼ 19% vs 2024 (€ 248,261) Unfavourable step	▼ 19%
Total debts	€ 635,359 Total debts 2022: € 635,359 First fiscal year in the series	€ 373,083 Total debts 2023: € 373,083 ▼ 41% vs 2022 (€ 635,359) Favourable step	€ 442,157 Total debts 2024: € 442,157 ▲ 19% vs 2023 (€ 373,083) Unfavourable step	€ 527,974 Total debts 2025: € 527,974 ▲ 19% vs 2024 (€ 442,157) Unfavourable step	▲ 19%
Cash	€ 437,302 Cash 2022: € 437,302 First fiscal year in the series	€ 230,178 Cash 2023: € 230,178 ▼ 47% vs 2022 (€ 437,302) Unfavourable step	€ 288,161 Cash 2024: € 288,161 ▲ 25% vs 2023 (€ 230,178) Favourable step	€ 358,395 Cash 2025: € 358,395 ▲ 24% vs 2024 (€ 288,161) Favourable step	▲ 24%
Land & buildings	€ 290,146 Land & buildings 2022: € 290,146 First fiscal year in the series	€ 317,213 Land & buildings 2023: € 317,213 ▲ 9% vs 2022 (€ 290,146) Unchanged	€ 344,960 Land & buildings 2024: € 344,960 ▲ 9% vs 2023 (€ 317,213) Unchanged	€ 347,374 Land & buildings 2025: € 347,374 ▲ 1% vs 2024 (€ 344,960) Unchanged	▲ 1%
Retained profit	€ 118,964 Retained profit 2022: € 118,964 First fiscal year in the series	€ 262,063 Retained profit 2023: € 262,063 ▲ 120% vs 2022 (€ 118,964) Favourable step	€ 238,261 Retained profit 2024: € 238,261 ▼ 9% vs 2023 (€ 262,063) Unfavourable step	€ 191,191 Retained profit 2025: € 191,191 ▼ 20% vs 2024 (€ 238,261) Unfavourable step	▼ 20%
Dividend	€ 350,000 Dividend 2022: € 350,000 First fiscal year in the series	€ 135,000 Dividend 2023: € 135,000 ▼ 61% vs 2022 (€ 350,000) Unchanged	€ 240,000 Dividend 2024: € 240,000 ▲ 78% vs 2023 (€ 135,000) Unchanged	€ 325,000 Dividend 2025: € 325,000 ▲ 35% vs 2024 (€ 240,000) Unchanged	▲ 35%
Bank debt	€ 227,527 Bank debt 2022: € 227,527 First fiscal year in the series	€ 210,569 Bank debt 2023: € 210,569 ▼ 7% vs 2022 (€ 227,527) Favourable step	€ 193,962 Bank debt 2024: € 193,962 ▼ 8% vs 2023 (€ 210,569) Favourable step	€ 176,629 Bank debt 2025: € 176,629 ▼ 9% vs 2024 (€ 193,962) Favourable step	▼ 9%
Balance sheet total	€ 764,323 Balance sheet total 2022: € 764,323 First fiscal year in the series	€ 645,146 Balance sheet total 2023: € 645,146 ▼ 16% vs 2022 (€ 764,323) Unchanged	€ 690,418 Balance sheet total 2024: € 690,418 ▲ 7% vs 2023 (€ 645,146) Unchanged	€ 729,165 Balance sheet total 2025: € 729,165 ▲ 6% vs 2024 (€ 690,418) Unchanged	▲ 6%

Key figures of Dr. Katrien Wierckx, endocrinologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Katrien Wierckx, endocrinologie?

What happened at Dr. Katrien Wierckx, endocrinologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 27, 2026 New annual accounts for financial year 2025: profit of € 277,930 (▲ 29% vs 2024). filed late Source: NBB ↗
Jul 17, 2019 New establishment in Oosterzele. KBO
Jul 17, 2019 Start of the company according to the CBE. KBO

In short

From € 151,278 profit in 2022 to € 277,930 profit in 2025.

Paid € 285,008 in corporate taxes since 2022.

Best year ever: 2023, with € 278,098 profit.

Paid out € 1.1 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Katrien Wierckx, endocrinologie? We notify you, reason included.

Follow Dr. Katrien Wierckx, endocrinologie

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Katrien Wierckx

Dr. Katrien Wierckx, endocrinologie

Behind Dr. Katrien Wierckx, endocrinologie is Katrien Wierckx.

See the full network in the app

Directors

According to the 2025 annual accounts

Katrien Wierckx

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Rattepas 11A

9860 Oosterzele

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0730.804.532
VAT number: BE 0730.804.532
Registered office: Rattepas 11A, 9860 Oosterzele
Names & denominations: Dr. Katrien Wierckx, endocrinologie
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 17 July 2019
Peppol: Active · Active since 31 Oct 2023
Contact: [email protected] +32474467892
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗